Investigational Drug Information for Moclobemide
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
What is the drug development status for Moclobemide?
Moclobemide is an investigational drug.
There have been 7 clinical trials for Moclobemide. The most recent clinical trial was a Phase 3 trial, which was initiated on December 30th 2023.
The most common disease conditions in clinical trials are Sialorrhea, Panic Disorder, and Anxiety Disorders. The leading clinical trial sponsors are Beersheva Mental Health Center, Tirat Carmel Mental Health Center, and Forest Laboratories.
There are nine hundred and fourteen US patents protecting this investigational drug and twelve international patents.
Summary for Moclobemide
|US Patent Applications||3,919|
|WIPO Patent Applications||1,765|
|Japanese Patent Applications||804|
|Clinical Trial Progress||Phase 3 (2023-12-30)|
Recent Clinical Trials for Moclobemide
|Efficacy of Hydroxyzine for Patients With Panic Disorder||Sultan Qaboos University||Phase 4|
|Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer||China Medical University Hospital||Phase 2|
|Pharmacovigilance in Gerontopsychiatric Patients||Hannover Medical School||Phase 3|
Clinical Trial Summary for Moclobemide
Top disease conditions for Moclobemide
Top clinical trial sponsors for Moclobemide
US Patents for Moclobemide
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Moclobemide||See Plans and Pricing||Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders||Dana-Farber Cancer Institute, Inc. (Boston, MA)||See Plans and Pricing|
|Moclobemide||See Plans and Pricing||Methods and compositions for treating infection||UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS)||See Plans and Pricing|
|Moclobemide||See Plans and Pricing||Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators||Reset Therapeutics, Inc. (South San Francisco, CA)||See Plans and Pricing|
|Moclobemide||See Plans and Pricing||Heterocyclic flavone derivatives, compositions, and methods related thereto||Emory University (Atlanta, GA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
International Patents for Moclobemide
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Moclobemide||World Intellectual Property Organization (WIPO)||WO2016085784||2034-11-26||See Plans and Pricing|
|Moclobemide||Australia||AU2011210567||2030-01-29||See Plans and Pricing|
|Moclobemide||Canada||CA2787784||2030-01-29||See Plans and Pricing|
|Moclobemide||European Patent Office||EP2528893||2030-01-29||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|